Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal fractional-dose Moderna COVID-19 vaccine study in healthy adults
NL-OMON51021Phase 2Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elasomeran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Leiden University Medical Center. Primary endpoints: Local reactogenicity, Systemic reactogenicity and 5 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51021.